2018 American Society of Hematology Annual Meeting*

Investigational anti-CD33 antibody–drug conjugate with a novel mechanism of action demonstrated preliminary antileukemia activity and tolerability in dose-escalation study.

Nearly all patients who received sequential HCVAD with blinatumomab achieved MRD-negative status.

Frontline blinatumomab with POMP maintenance was well tolerated with no early deaths in this cohort of patients aged 65 years or older.

Early results show addition of blinatumomab to inotuzumab ozogamicin plus mini-HCVD efficacious in older patients with newly diagnosed Ph- ALL.

Nonrandomized, observational study suggests reduced event-free survival in patients receiving generic vs branded imatinib.

Venetoclax with HMA active and tolerable in hard-to-treat elderly AML patients.

Long-term OS benefit was observed in patients with Ph-negative ALL, particularly those who achieved complete MRD response after the first cycle of blinatumomab or while in first CR

In patients with newly diagnosed AML with IDH1 or IDH2 mutations, addition of ivosidenib or enasidenib to standard chemotherapy was associated with good tolerability, mutation clearance, and MRD negativity.

In patients with R/R FLT3-ITD–mutated AML, single-agent quizartinib significantly prolongs survival compared with salvage chemotherapy with a low incidence of grade 3 QT prolongation.

Combination of the FLT3 inhibitor gilteritinib with standard intensive chemotherapy was active and tolerable as first-line AML therapy.

Sorafenib maintenance therapy after transplantation significantly reduced the disease relapse rate and improved survival compared with placebo in patients with FLT3-ITD AML.